MarketPulse

CAR T-cell therapy

15 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Plasmid DNA Market Set to Quadruple to $10.8B by 2034 on Gene Therapy Boom

Plasmid DNA manufacturing market projected to reach $10.8B by 2034 from $2.4B in 2025 on strong gene therapy demand growth.
TMODHRCRLLZAGYWUXAYgene therapyCAR T-cell therapy
The Motley FoolThe Motley Fool··Adria Cimino

CRISPR Therapeutics Eyes $223B Autoimmune Market With Gene-Editing Breakthrough

CRISPR Therapeutics leverages FDA-approved gene editing to target a $223B autoimmune disease market, positioning itself as the post-GLP-1 growth opportunity in biotech.
LLYVRTXNVOCRSPclinical trialsgene therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Kyverna's Miv-cel Shows Durable Benefits in Stiff Person Syndrome Trial

Kyverna's miv-cel shows statistically significant benefits across all endpoints in stiff person syndrome trial, with 81% achieving meaningful walking speed improvement.
KYTXclinical trialautoimmune disease
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Oncolytic Virus Immunotherapy Market Poised to Reach $5B by 2031

Global oncolytic virus immunotherapy market projected to exceed $5 billion by 2031, driven by three approved therapies and 150+ clinical candidates advancing combination approaches.
BMYCELGrMRKRHHBYREPL+1clinical trialscancer treatment
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Myasthenia Gravis Market Poised for Transformation With 8 Late-Stage Drug Candidates

Generalized myasthenia gravis market valued at $5.9B in 2025, projected to grow 9.1% annually through 2036 as eight promising late-stage therapies advance.
NVSAZNREGNMKKGYROIV+3clinical trialsautoimmune disease
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Allogene Therapeutics Raises $175M Via Stock Offering to Fund Clinical Pipeline

Allogene prices 87.5M shares at $2.00 each, raising $175M gross proceeds for clinical trials and R&D operations.
ALLOclinical trialspublic offering
The Motley FoolThe Motley Fool··James Halley

CRISPR's $2B War Chest Powers Gene-Therapy Expansion as Casgevy Sales Accelerate

CRISPR Therapeutics holds $2B cash reserves funding gene-therapy expansion, while Casgevy sales accelerate to $116M in 2025.
CRSPbiotechclinical trials
BenzingaBenzinga··Usanewsgroup.Com News Commentary

Cell Therapy Manufacturing Boom: $14B Market Opportunity Reshapes Biotech Landscape

Global cell therapy manufacturing market projected to reach $14B by 2035, with FDA regulatory flexibility accelerating approvals and multiple biotech companies advancing scalable production capabilities.
IBRXFATEMBRXAVAIGUTSCAR T-cell therapyMaster Cell Bank
GlobeNewswire Inc.GlobeNewswire Inc.··Autolus Therapeutics Plc

Autolus Therapeutics Posts $74.3M Revenue as AUCATZYL Scales Across Europe

Autolus Therapeutics reported $74.3M in 2025 AUCATZYL revenue with UK launch underway. Company projects $120-135M in 2026 revenue and positive gross margin expansion.
AUTLFDA approvalclinical trials
The Motley FoolThe Motley Fool··Jonathan Ponciano

Cormorant's $64M Arcellx Exit Preceded 77% Gilead Takeover Surge

Cormorant Asset Management exited its $63.63M Arcellx stake in Q4, missing an 80% year-to-date rally capped by Gilead Sciences' $7.8B acquisition announcement.
GILDACLXfund exitoncology
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Tempest Advances CAR-T Program With Manufacturing Deal Ahead of 2026 FDA Filing

Tempest Therapeutics partners with Cincinnati Children's for TPST-2003 manufacturing, targeting U.S. registrational study launch in 2026 following strong interim trial results.
TPSTclinical trialmultiple myeloma
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Bristol Myers' Abecma Poised for Explosive Growth as CAR-T Therapy Expands Beyond Relapsed Myeloma

Abecma CAR-T therapy market surging on rising myeloma cases and regulatory wins. BMS-backed treatment faces headwinds from tariffs but eyes earlier-line expansion.
BMYCELGrregulatory approvalmultiple myeloma
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Lyell Immunopharma Secures $50M Funding Tranche on Clinical Progress

Lyell Immunopharma closes $50M funding tranche, advances ronde-cel in pivotal lymphoma trial, appoints new CFO with extended cash runway through Q2 2027.
LYELCAR T-cell therapycash runway
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Kyverna Bolsters Board With Beam, Karuna Executives Ahead of Cell Therapy Launch

Kyverna appoints two biotech executives to its board ahead of cell therapy commercialization. New directors bring expertise from Beam Therapeutics and Karuna Therapeutics.
BMYCELGrKYTXBEAMclinical developmentautoimmune diseases
BenzingaBenzinga··Vandana Singh

Gilead to Acquire Arcellx for $7.8B to Expand CAR-T Oncology Portfolio

Gilead acquires Arcellx for $7.8B to gain CAR-T therapy anito-cel for multiple myeloma, with FDA approval expected by late 2026.
GILDACLXacquisitionFDA approval